BackBeat CNT
Commercial- Indications
- Hypertension, Isolated systolic hypertension
Company intelligence / Profile preview
The company’s AVIM/CNT device has demonstrated statistically significant reductions in blood pressure for hypertensive patients with an indication for a pacemaker. In the MODERATO I and II pilot studies, the device showed immediate and persistent blood pressure lowering effects. The pivotal BACKBEAT IDE study was approved by FDA in September 2023 and is ongoing. Strategic partnership with Medtronic to support development and potential commercialization if approved. Therapy remains investigational.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BackBeat Medical.